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Abstract
Background/Aims—Liver regeneration after partial hepatectomy (PH) in retrorsine-exposed rats
is accomplished through proliferation and differentiation of small hepatocyte-like progenitor cells
(SHPCs). The cells of origin of SHPCs are not known. We investigated the possibility that SHPCs
are directly derived from oval cells, a known liver progenitor cell, by combining the retrorsine/PH
(RP) model with 2-acetamidofluorene (2-AAF), an anti-mitotic agent that elicits an oval cell reaction
in response to liver deficit.
Methods—Male Fischer 344 rats were treated with retrorsine (30 mg/kg ip) at 6 and 8 weeks of
age, with PH 5 weeks after the final treatment. Seven days prior to PH, a 21 day 2-AAF (50 mg)
time-release pellet was inserted subcutaneously. Livers were harvested at 3, 7, 10, 14, and 21-days
post-PH.
Results—Liver sections from animals treated with 2-AAF/retrorsine/PH (2-AAF/RP) contain
significant numbers of proliferating oval cells, but no SHPCs at 7-days post-PH, while RP animals
exhibit significant numbers of SHPCs and minimal oval cell reaction. Between 10 and 14-days post-
PH, new hepatocyte clusters appear in 2-AAF/RP treated rats. Labeling of proliferating oval cells
with BrdU at 6-days post-PH demonstrated that these new hepatocytes represent the progeny of
differentiating oval cells.
Conclusions—The observed differences in progenitor cell responses between 2-AAF/RP and RP
animals strongly suggest that SHPCs are not the progeny of oval cell precursors, but represent an
independent liver progenitor cell population.
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1. Introduction
The mammalian liver possesses an enormous capacity to replace cells that are lost to surgical
resection or necrosis (1), and several different cell populations can be activated to repair or
regenerate the liver depending upon the nature and extent of injury or tissue deficit (2). In an
otherwise healthy liver, replacement of hepatocytes and biliary epithelia is achieved through
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the proliferation of mature (fully-differentiated) hepatocytes and biliary epithelial cells
contained in the residual (viable) tissue (2,3). Activation of undifferentiated stem cells does
not occur when these mature cell types are capable of proliferating to restore liver mass and
structure (4). However, in several experimental models, hepatocytes are rendered unable to
proliferate through exposure to mitoinhibitory compounds, resulting in the emergence and
proliferation of stem-like progenitor cells in response to liver deficit (3,5). Numerous studies
have appeared that describe the outgrowth of undifferentiated oval cells after hepatocellular
injury (1,5,6). Oval cells respond to liver damage in the presence of mitoinhibitory agents that
block hepatocyte proliferation [such as 2-acetamidofluroene (2-AAF)], as well as agents that
cause necrosis (galactosamine) (7,8). Our group and others described the cellular responses
and time-course for liver regeneration after surgical partial hepatectomy (PH) in rats with
retrorsine-induced hepatocellular injury (9,10). Systemic exposure to retrorsine, a member of
the pyrrolizidine alkaloid family, results in a severe inhibition of the replicative capacity of
fully-differentiated hepatocytes (11,12). When confronted with a strong proliferative stimulus
such as PH (10–12), retrorsine-injured hepatocytes synthesize DNA, but are unable to complete
mitosis, and arrest as non -proliferative giant cells (megalocytes) (10). In this model, the entire
liver mass is reconstituted after PH through the emergence and expansion of a population of
small hepatocyte-like progenitor cells (SHPCs) (10,13), concurrent with apoptosis of retrorsine
injured hepatocytes (10,14).
The origin of SHPCs is commonly debated and remains unknown. Data from recent studies
provide contradictory results suggesting that either oval cells or mature hepatocytes are the
origin of the SHPCs (15,16). We have investigated the possibility that SHPCs are the progeny
of oval cells by combining the retrorsine/PH (RP) model of liver injury with 2-AAF treatment.
We describe distinct differences in progenitor cell responses to liver deficit in animals exposed
to (i) retrorsine and 2-AAF, (ii) retrorsine only, or (iii) 2-AAF only. Animals treated with both
retrorsine and 2-AAF before PH contain robust oval cell proliferation by 3-days post-PH, with
continued oval cell expansion between 3 and 10 days, and formation of new hepatocytes by
14-days post-PH. Animals exposed to retrorsine (in the absence of 2-AAF) never exhibit
substantial oval cell proliferation, but clusters of SHPCs emerge as early as 3 days after PH
and expand to regenerate the liver over a period of several weeks. Animals receiving 2-AAF
only or retrorsine only never exhibit oval cells or SHPCs at any time point. These results suggest
that exposure to 2-AAF impairs the emergence and outgrowth of SHPCs. Consistent with this
suggestion, 2-AAF treatment 7-days post-PH in retrorsine-exposed rats results in the blockade
of SHPC expansion. The results of this investigation fail to establish a precursor-product
relationship between oval cells and SHPCs and suggest that SHPCs are susceptible to the mito-
inhibitory effects of 2-AAF. Based upon these observations we conclude that SHPCs are not
the progeny of oval cells, but represent a distinct liver progenitor cell population.
2. Materials & Methods
2.1. Animals
Male Fischer 344 rats were purchased from Charles River Laboratories (Wilmington, MA) or
bred and maintained in the AAALAC-accredited animal facilities of the University of North
Carolina at Chapel Hill. All procedures involving animals were carried out in accordance with
federal and state guidelines put forth by the NIH and the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill.
2.2. Retrorsine and 2-Acetamidofluorene Administration, and Partial Hepatectomy
Male six week-old littermate Fischer 344 rats were randomized into retrorsine treatment (n=76)
and control (n=110) groups at the outset of the experiment. Rats in the retrorsine treatment
group received two treatments of retrorsine (30 mg/kg i.p.) two weeks apart (at 6 and 8 weeks
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of age). Retrorsine (12,18-Dihydroxysenecionan-11,16-dione; β-Longilobine, Sigma
Chemical Company, St. Louis, MO) was added to distilled water at 10 mg/ml and titrated to
pH 2.5 with 1 N HCl to completely dissolve the solid. Subsequently, the solution was
neutralized using 1 N NaOH, and NaCl was added for a final concentration of 6 mg/ml
retrorsine and 0.15 M NaCl (pH=7.0). The working solution was administered immediately
after preparation. Four weeks following the second retrorsine treatment, experimental and
control rats were randomized into the following experimental groups: retrorsine/PH (n=27),
2-AAF/retrorsine/PH (n=38), 2-AAF/PH (n=42), placebo/PH (n=31), 2-AAF only (n=18),
placebo only (n=19), retrorsine/PH + 2-AAF (n=6), retrorsine/PH + placebo (n=5) (Fig. 1).
Animals that were to receive 2-AAF treatment were implanted with 21-day controlled release
50 mg pellets which delivered an approximate dose of 10 mg/kg 2-AAF daily (Innovative
Research, Sarasota, FL). Control animals were implanted with a placebo pellet (Innovative
Research). One week later (5 weeks after the second retrorsine treatment), two-thirds surgical
PH was performed on select experimental groups and on control rats of similar age (13 weeks
old), essentially as originally described (17). Due to significant mortality in the 2-AAF/PH and
2-AAF/RP groups, only 130 (70%) rats survived the experimental protocol and these rats are
included in the results presented. At 3, 7, 10, 14, and 21-days after PH liver tissue was harvested
from n=3–7 rats (except for the 2-AAF/RP and 2-AAF/PH 21- day post-PH groups where n=2)
and fixed in 10% neutral buffered formalin.
2.3. Bromodeoxyuridine Treatment
Select animals were treated with 5-bromo-2′-deoxyuridine (100 mg/kg i.p.) 6-days post-PH
(Sigma Chemical Company). The working solution was prepared by dissolving the solid into
a saline solution at 33.3 mg/mL. This solution was heated using hot tap water and vortexed
vigorously to dissolve the solid. The working solution was administered immediately following
preparation.
2.4. Histology and Morphometry
Routine paraffin-embedding, sectioning, and preparation of H&E stained tissue sections from
formalin-fixed liver tissue was performed by Histo-Scientific Research Laboratories (Mount
Jackson, VA). Morphometric analysis was performed by digitally scanning H&E stained slides
using an Aperio Scanscope T2 Virtual Microscope System (Vista, CA) at a resolution of 0.4667
μm/pixel. Images were analyzed using Aperio Imagescope v6.25 software. SHPC clusters were
identified in the H&E sections based upon cell morphology and arrangement. Using the various
tools provided by the Imagescope v6.25 software, SHPC clusters were enumerated and
measured (area). All data obtained using Imagescope v6.25 was normalized to the cross
sectional area of the tissue section, measured using Image J v1.36 software (National Institutes
of Health, Bethesda, MD).
2.5. Immunohistochemistry
Colorimetric immunoperoxidase analysis was carried out on paraffin-embedded tissue sections
using standard procedures. Tissue sections were deparaffinized in xylene, washed through a
gradient of ethanol solutions (100%, 95%, and 70%), and rehydrated in a phosphate buffered
saline (PBS) solution (1.54 mM KH2PO4, 155.17 mM NaCl, 2.71 mM NaH2PO4-7H2O; pH
7.2). Endogenous peroxidase activity was quenched for 10 minutes using a 0.3% H202 solution
diluted in 100% methanol. Antigen retrieval was achieved by placing the slides in a heated 10
mM citrate antigen retrieval buffer (DakoCytomation) and subsequently placing the slide
chamber (with buffer) in a steamer for 30 minutes. Non-specific antibody binding was blocked
with a serum-free protein block (DakoCytomation) and primary antibodies were detected with
the DakoCytomation Labelled Streptavidin-Biotin2, Horseradish Peroxidase (LSAB2®, HRP)
system (DakoCytomation). The secondary antibody was detected using a substrate containing
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diaminobenzidine (DakoCytomation). Tissue sections were counterstained using Mayer’s
hematoxylin (Sigma Chemical Company). Primary antibodies were diluted using antibody
diluent with background reducing components (DakoCytomation). Mouse anti-rat BrdU
antibody (Abcam, Cambridge, MA) and mouse anti-human cytokeratin 19 antibody
(DakoCytomation) were used at a dilution of 1:25.
2.6. Data Analysis
The numerical data presented in figures and tables represent the mean ± standard error of the
mean (SEM). All statistical analyses were performed using Kaleidograph v4.0 (Synergy
Software, Reading, PA). Mean SHPC cluster sizes were calculated using each individual
cluster as a separate event. All additional analyses were performed using individual animals
as separate events. Significance of quantitative data was calculated using Student’s two-tailed
t-test with unequal variance among groups. A statistically significant difference in data was
defined by a P<0.05.
3. Results
3.1. Regenerative responses after PH in rats exposed to retrorsine alone and retrorsine in
combination with 2-AAF
At 3-days following PH, RP animals have liver weights and liver/body weight ratios
comparable to that observed in 2-AAF/PH animals (P>0.05 for RP versus 2-AAF/PH) (Fig.
2B, 2C). RP animals have low liver weights and liver/body weight ratios through 14-days post-
PH, and then show a moderate increase in liver weight at 21-days post-PH (Fig 2B, 2C).
Animals in the 2-AAF/RP group have liver weights that are not significantly different (P>0.05)
from those observed in RP animals for the first 14-days post-PH (Fig. 2B). The lack of
increasing liver weights among these animals during the first 14-days post-PH does not reflect
a lack of regenerative activity. Rather, retrorsine-injured hepatocytes undergo megalocytosis
following PH, and then apoptosis as new cells are generated in response to liver deficit (10).
Animals in the 2-AAF/RP group show a dramatic increase in liver weight between 14 and 21-
days post-PH and have liver weights that are indistinguishable from placebo/PH control
animals at 21-days post-PH (P>0.05 for 2-AAF/RP versus placebo/PH) (Fig. 2B). In contrast,
2-AAF/PH animals have low liver weights through 7-days post-PH, with a moderate increase
in liver size at 10-days post-PH, and becoming indistinguishable (P>0.05 for 2-AAF/PH versus
placebo/PH) from control (placebo/PH) by 14-days post-PH (Fig 2B). Likewise, 2-AAF/PH
animals demonstrate an increase in liver/body weight ratios by 14-days post-PH and attain a
control liver/body weight ratio by 21-days post-PH (P>0.05 for 2-AAF/PH versus placebo/
PH) (Fig. 2C). Together, these results suggest that the timing and kinetics of liver regeneration
after PH in retrorsine-exposed animals treated with 2-AAF is similar to that observed in 2-
AAF/PH animals.
Analysis of H&E stained liver sections showed that the nature of the regenerative responses
observed in RP and 2-AAF/RP animals differ significantly. Liver tissue harvested from RP
animals at 3-days post-PH contain emerging SHPC clusters and modest numbers of oval cells
(Fig. 3A). At this same time point post-PH in animals treated with 2-AAF, oval cells begin to
appear in large numbers and SHPCs are not observed (Fig. 3B–C). By 7-days post-PH, liver
from RP animals show a robust SHPC response with numerous proliferating cell clusters and
very little oval cell proliferation (Fig. 3E). In contrast, livers harvested at this time point from
2-AAF/RP and 2-AAF/PH rats exhibit marked proliferation of oval cells, but SHPCs are not
observed (Fig. 3F–G). At 10-days post-PH RP animals exhibit large numbers of proliferating
SHPC clusters (Fig. 3I). In contrast, SHPCs are not observed in livers harvested from 2-AAF/
RP (Fig. 3J) and 2-AAF/PH (Fig. 3K) animals at this time point. At 14-days post-PH a
population of phenotypically ‘small’ hepatocytes appear in the 2-AAF/RP and 2-AAF/PH
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animals (Fig. 3N–O). These hepatocytes are found in close proximity to proliferating oval cells
suggesting that these cells are the differentiated progeny (i.e. new hepatocytes) of the oval cells
(Fig. 3N–O). Livers from RP animals at this time-point did not contain significant numbers of
oval cells, but contained large numbers of expanding SHPC clusters (Fig. 3M). Neither SHPC
clusters nor oval cells are observed at any time point after PH in placebo-treated animals (Fig.
3D, 3H, 3L, and 3P). Likewise, SHPC clusters and oval cells are not observed in 2-AAF only,
placebo only, and retrorsine only animals that were not surgically manipulated (data not
shown). The differences between progenitor cell responses observed during liver regeneration
in RP and 2-AAF/RP animals suggest that although the SHPCs (and their progenitors) are
resistant to the mito-inhibitory effects of retrorsine, they may be susceptible to 2-AAF
poisoning.
3.2. Immunohistochemical analysis of 2-AAF-treated retrorsine-exposed rat liver
Immunostaining of the oval cell and biliary tract marker cytokeratin 19 (ck19) clearly labeled
proliferating oval cells (along with biliary epithelia) in 2-AAF/PH and 2-AAF/RP rats at 7-
days post-PH (Fig. 4A, 4C). At 14-days post-PH in 2-AAF/PH animals, ck19-positive oval
cells surround new hepatocyte clusters (Fig. 4B). The new hepatocytes were weakly positive
for ck19 (Fig. 4B). This observation suggests that the new hepatocytes represent the progeny
of proliferating/differentiating oval cells, as observed by others (18). Likewise, ck19-positive
oval cells surround new hepatocyte clusters in livers of 2-AAF/RP animals at 14-days post-
PH (Fig. 4D). In contrast, ck19 immunostaining of livers from RP animals at 7 days and 14-
days post-PH decorated the modest oval cell response, but failed to reveal ck19-positive oval
cells in close proximity to SHPC clusters (Fig. 4E–F). Rather ck19 immunostaining exclusively
labeled biliary tracts in these animals (Fig. 4E–F). These results provide additional evidence
that the oval cell response in RP rats is modest and that identifiable oval cells do not obviously
feed into SHPC clusters.
3.3. BrdU labeling demonstrates that new hepatocyte clusters observed in 2-AAF-treated
animals are the progeny of oval cells
To investigate the lineage relationship between oval cells and hepatocytes observed in 2-AAF-
treated animals we treated 2-AAF/RP and 2-AAF/PH rats with BrdU (100 mg/kg i.p.) 6-days
after PH. As previously described (19–21), treatment with BrdU 6-days post-PH exclusively
labels oval cells in animals receiving 2-AAF before PH (Fig. 5A, 5C). By 14-days post-PH
BrdU-positive cells are observed in 100% of the newly formed hepatocyte clusters in 2-AAF/
PH (Fig. 5B) and 2-AAF/RP animals (Fig. 5D). These results demonstrate that new hepatocyte
clusters observed in 2-AAF/PH and 2-AAF/RP animals are the progeny of proliferating/
differentiating oval cells.
3.4. Treatment with 2-AAF after PH blocks SHPC cluster expansion
To directly address the possibility that SHPCs are susceptible to the mito-inhibitory effects of
2-AAF poisoning, we treated rats with the standard RP protocol followed by the addition of
2-AAF after the initiation of SHPC proliferation (Fig. 6). One week following PH, rats were
treated with either a placebo (n=5) or a 2-AAF (n=6) controlled time release pellet and livers
were collected 7 days later (14-days post-PH). Morphometric analysis of H&E stained tissue
from these animals demonstrated that SHPC clusters in animals receiving 2-AAF ceased to
expand after administration of 2-AAF, suggesting that the proliferation of SHPC was inhibited
by 2-AAF exposure (Fig 6D and Table 1). The size of SHPC clusters observed in RP + 2-AAF
animals at 14-days post-PH were indistinguishable (P>0.05 for RP 7-day post-PH versus RP
+ 2-AAF 14-day post-PH) from those observed in RP animals at 7-days post-PH (Fig. 6D and
Table 1). In contrast, SHPC clusters in RP + placebo animals continue to expand and by 14-
days post-PH are approximately two-fold larger than those observed in RP + 2-AAF animals
Best and Coleman Page 5













(Table 1 and Fig 6E). There were no differences (P>0.05 for RP versus RP + placebo at 14-
days post-PH) in the size of SHPC clusters observed in RP animals receiving placebo pellets
and RP animals (in the absence of placebo) at 14-days post-PH (Table 1). These data directly
demonstrate that SHPCs are susceptible to 2-AAF poisoning and suggest that SHPCs are not
the progeny of 2-AAF resistant oval cells.
4. Discussion
In the past the presence of a stem cell population in the adult liver has been the topic of debate.
This controversy is largely due to the lack of high cellular turnover in the liver that is observed
in other organs that are known to contain a classic, stem-cell-fed lineage system (i.e. colon,
bone marrow, etc.) (22–24). The presence of a liver stem cell was further questioned because
mature hepatocytes are capable of restoring lost tissue mass after surgical resection or injury,
making a liver stem cell appear unnecessary. However, mounting evidence over the past several
years has led to the general acceptance of the presence of cell population(s) with stem-like
properties in the livers of adult rodents (3). These cells vary from (i) propagable multipotential
stem-like cells (i.e. WB-F344, RLE-13, and others derived from liver epithelial cells) capable
of differentiating into cells of both hepatic and extrahepatic tissues (2), (ii) bipotential stem-
like cells (i.e. oval cells) capable of differentiating into mature hepatocytes and biliary epithelia
(1,6), and (iii) unipotential cells (i.e. SHPCs) capable of differentiating into mature hepatocytes
(3). Our focus is on the regenerative responses mediated by bipotential and unipotential stem-
like cells.
Bipotential stem-like cells are thought to respond to tissue deficit when mature hepatocytes
are damaged and incapable of proliferating to restore lost liver mass. One example of a
bipotential progenitor cell with stem-like properties is the oval cell, which is generally believed
to reside in the bile ducts or periportal region of the liver (25). Oval cells exhibit a less
differentiated phenotype than mature hepatocytes, expressing markers of fetal hepatoblasts,
hematopoietic stem cells, and biliary epithelia (6). These cells are closely associated with liver
injury models where animals are exposed to mito-inhibitory agents that block hepatocyte
division (i.e. 2-AAF) (8). Several studies have demonstrated that oval cells are capable of
differentiating into hepatocytes in a short time course after PH in a dose dependent manner
(18,21,26).
In addition to oval cells there are other potential stem-like progenitor cell populations in the
adult rodent liver that respond to toxic liver injury. Several studies have reported the presence
of a population of cells termed small hepatocyte-like progenitor cells (SHPCs) that are closely
associated with exposure to the pyrrolizidine alkaloid retrorsine (9,10,13,15,16). The ability
of SHPCs to differentiate into cells of the biliary lineage has not been shown. Therefore, SHPCs
are considered an example of unipotential stem-like progenitor cells that can differentiate into
mature hepatocytes. Recently, the cellular origins of SHPCs have been the subject of
controversy and some investigators have suggested that SHPCs and oval cells might represent
the same (or closely related) population of cells (6). There are several potential sources for
SHPCs (Fig. 7) and recent studies were conducted to address the cellular origins of SHPCs.
These studies produced extremely varied results. Avril et al. employed a retroviral-based model
to genetically label mature hepatocytes with the β-galactosidase gene in retrorsine-exposed
Sprague-Dawley rats before PH to determine the contribution of mature hepatocytes to the
formation of SHPC clusters in this model of liver injury (15). This study showed that a
significant number of SHPC clusters expressed β-galactosidase and based upon this evidence
concluded that mature hepatocytes are the source of SHPCs (15). However, this study failed
to rule out the potential contributions of other cell types. For example, the investigators never
specify the percentage of biliary epithelial cells and other extrahepatic cells that were labeled
with β-galactosidase gene using this retroviral-based method (13). Therefore, it is impossible
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to determine if oval cells or some other cell type contributed to the formation of SHPC clusters
in these animals (13). A more recent study by Vig et al. used a hepatitis B surface antigen
(HBsAg-tg) mouse model of chronic liver injury to study the origins of the SHPCs (16). This
study used three dimensional mapping techniques to demonstrate that livers of retrorsine-
exposed HBsAg-tg mice exhibit SHPC proliferation, and that these clusters were both
surrounded and infiltrated by proliferating oval cells (16). However, the investigators note that
not all of the SHPCs observed are positive for oval cell markers and conclude that other cell
types may possibly contribute to the formation of these cell clusters (16). The original model
of retrorsine-induced liver injury is based upon acute injury and regeneration in rats (10,11).
Thus, it is difficult to discern if the cell clusters observed in the chronic HBsAg-tg mouse model
are the same cell type (i.e. SHPCs) observed in RP rats. Moreover, it is known that oval cells
differentiate into phenotypically ‘small’ hepatocytes before becoming mature hepatocytes
(18). Thus, it is possible that the cells observed in this model are not SHPCs, but new hepatocyte
progeny of proliferating oval cells. Combined, these published studies leave numerous
unanswered questions about the origins of the SHPCs. Are SHPCs derived from a population
of retrorsine-resistant hepatocytes? Are these cells the progeny of oval cells? Do these cells
represent an independent reserve progenitor cell population?
In the current study we investigated the contribution of oval cells to the formation of SHPCs
by combining the RP model of liver injury (10,11) with 2-AAF treatment. Based on the CYP450
expression profile observed in SHPCs (9,27) and differences in the requirements for retrorsine
and 2-AAF metabolism we hypothesized that retrorsine-resistant SHPCs (or their precursors)
would be susceptible to 2-AAF poisoning. In fact, we observed that SHPCs do not represent
a regenerative cell population in retrorsine-exposed animals treated with 2-AAF, but that the
livers of these animals are reconstituted through the outgrowth, expansion, and differentiation
of oval cells. Two lines of evidence support the suggestion that SHPCs (or their precursors)
are sensitive to 2-AAF treatment: (i) no SHPCs are observed in 2-AAF/RP animals and (ii)
administration of 2-AAF to RP rats inhibits SHPC proliferation. In contrast, oval cells readily
emerge and proliferate in animals treated with retrorsine (2-AAF/RP). Furthermore, the timing
and nature of the cellular responses in 2-AAF/PH and 2-AAF/RP animals was
indistinguishable, and consistent with published studies (18,28). These results provide
significant new evidence that SHPCs are not derived from oval cells. We suggest that SHPCs
represent a novel parenchymal stem-like progenitor cell that participates in liver regeneration
following specific forms of liver injury.
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Experimental design timeline for retrorsine/2-AAF study. A timeline indicating the age of
animals (weeks) at the various times of treatment in this study is provided. R indicates the time
points for retrorsine injection (30 mg/kg each). 2-AAF indicates the time of insertion of a 21
day time-release 2-acetamidofluorene pellet (50 mg). Placebo indicates insertion of 21 day
time-release placebo pellet (50 mg). (A) Retrorsine treatment + Partial Hepatectomy (RP). (B)
Retrorsine treatment only (Retrorsine Only). (C) 2-AAF treatment + Partial Hepatectomy (2-
AAF/PH). (D) 2-AAF treatment + Retrorsine treatment + Partial Hepatectomy (2-AAF/RP).
(E) 2-AAF treatment only (2-AAF only). (F) Placebo treatment + Partial Hepatectomy
(Placebo/PH). (G) Placebo treatment only (Placebo only).
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Treatment with 2-AAF blocks the SHPC regenerative response but not liver regeneration in
retrorsine-exposed rats. The effects of 2-AAF treatment on (A) average body weight, (B)
average liver weight, and (C) average liver/body weight ratios are shown. Each bar represents
mean calculated from all surviving animals in the various experimental groups (± SEM, n=3–
7 per time point for all groups except for 21 day 2-AAF/RP and 2-AAF/PH where n=2). The
asterisks denote statistically significant differences (P<0.05) in liver weight (B) or liver/body
weight ratios (C) for the designated comparisons. NS denotes no significant difference
(P>0.05) for the designated comparison.
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SHPCs do not respond to liver deficit in retrorsine-exposed animals treated with 2-AAF.
Animals receiving standard retrorsine treatment and PH exhibit expanding SHPC clusters at
(A) 3-days, (E) 7-days, (I) 10-days, and (E) 14-days post-PH. Animals receiving both retrorsine
and 2-AAF exhibit large numbers of oval cells at (B) 3-days, (F) 7-days, and (J) 10-days post-
PH, and new hepatocyte formation is observed at (N) 14-days post-PH. Likewise, animals
receiving only 2-AAF exhibit large numbers of proliferating oval cells new at (C) 3-days, (G)
7-days, or (K) 10-days post-PH, and demonstrate some new hepatocyte cluster formation by
(O) 14 days after PH. Animals receiving placebo treatment do not exhibit oval cells or SHPC
clusters at (D) 3-days, (H) 7-days, (L) 10-days, or (P) 14-days post-PH. Short white arrows
indicate SHPC clusters, long black arrows indicate oval cells, and short black arrows indicate
new hepatocyte clusters. (Original objective lens magnification 10x).
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Immunostaining with oval cell marker cytokeratin 19. Cytokeratin 19 (ck19) staining in 2-
AAF/PH animals at (A) 7-days post-PH labels biliary epithelial cells and oval cells. and (B)
14-days post-PH labels biliary epithelial cells, oval cells and new hepatocyte clusters.
Likewise, ck19 immunostaining in 2-AAF/RP animals at (C) 7-days and (D) 14-days post-PH
labels biliary epithelial cells and oval cells surrounding new hepatocyte clusters. Ck19
immunostaining in RP animals at (E) 7-days and (F) 14-days post-PH only labels biliary tracts
in these animals. White arrows indicate ck19 positive biliary tracts, black arrows indicate new
hepatocyte clusters. (Original objective lens magnification 10x).
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Bromodeoxyuridine labeling demonstrates a precursor-product relationship between oval cells
and new hepatocyte clusters in 2-AAF-treated animals. Treatment with BrdU at 6-days post-
PH specifically labels oval cells in liver tissue collected at 7-days post-PH from 2-AAF treated
animals both in the (A) absence and (C) presence of retrorsine. By 14-days post-PH in animals
receiving only 2-AAF, BrdU-positive oval cells give rise to new hepatocytes clusters (B). A
similar result is seen at 14-days post-PH in retrorsine-exposed animals also treated with 2-AAF
(D). Colon taking from a BrdU-treated animal serves as a positive control (E) and colon taken
from an animal that was not treated with BrdU serves as a negative control (F). (Original
objective lens magnification 10x)
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Treatment with 2-AAF after PH in retrorsine-exposed rats blocks SHPC expansion. A timeline
indicating the age of animals (weeks) at the various times of treatment in this study is provided.
R indicates the time points for retrorsine injection (30 mg/kg each). 2-AAF indicates the time
of insertion of a 21 day time-release 2-acetamidofluorene pellet (50 mg). Placebo indicates
insertion of 21 day time-release placebo pellet (50 mg). (A) Retrorsine + parital hepatectomy
+ 2-AAF treatment 7-days post-PH (RP + 2-AAF). (B) Retrorsine + partial hepatectomy +
placebo treatment 7-days post-PH (RP + Placebo). H&E stained liver harvested from at 14-
days post-PH from (D) RP + 2-AAF animals exhibit SHPC clusters comparable in size to those
observed in (C) RP animals at 7-days post-PH. However, livers taken from (E) RP + Placebo
animals at 14-days post-PH exhibit SHPC clusters comparable to (F) RP animals at 14-days
post-PH. Arrows indicate SHPC clusters. (Original objected lens magnification 10x).
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Potential origins of the small hepatocyte-like progenitor cells. It is well established that oval
cells are derived from a periportal stem cell population. However, the origin of SHPCs is not
known and several cell populations could potentially be the progenitor cell giving rise to these
cells. These potential progenitor cell populations include a non-hepatocytic retrorsine-resistant
cells located in the liver parenchyma, a population of retrorsine-resistant mature hepatocytes,
or oval cells.
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